In head-to-head trials, tirzepatide produced greater reductions in the measured endpoints: superior HbA1c and weight loss in SURPASS-2, and a 20.2% versus 13.7% body-weight reduction in SURMOUNT-5
The usual GI side effects mean that patient education and monitoring are key for the best safety and adherence
News While semaglutide supply will be intermittent, its current availability should be enough for approved use, the manufacturer has advised
Food and Drug Administration (FDA) for the following medical conditions: For weight loss and long-term weight management in adults and pediatric patients aged 12 and older with obesity, and adults with overweight in the presence of at least one weight-related health condition, such as type 2 diabetes or high blood pressure
Myostatin deficiency has been studied in many species including mice, dogs, sheep, cattle and humans 46,47,48,49,50